Genelux Corp. (GNLX)
2.60
-0.06
(-2.26%)
USD |
NASDAQ |
Aug 31, 12:20
Genelux Enterprise Value : 103.73M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 103.73M |
| August 27, 2026 | 113.65M |
| August 26, 2026 | 106.88M |
| August 25, 2026 | 106.43M |
| August 24, 2026 | 106.43M |
| August 21, 2026 | 106.43M |
| August 20, 2026 | 107.33M |
| August 19, 2026 | 104.63M |
| August 18, 2026 | 101.02M |
| August 17, 2026 | 105.53M |
| August 14, 2026 | 107.33M |
| August 13, 2026 | 102.37M |
| August 12, 2026 | 105.53M |
| August 11, 2026 | 103.27M |
| August 10, 2026 | 106.43M |
| August 07, 2026 | 103.73M |
| August 06, 2026 | 105.53M |
| August 05, 2026 | 96.96M |
| August 04, 2026 | 110.94M |
| August 03, 2026 | 118.16M |
| July 31, 2026 | 116.35M |
| July 30, 2026 | 121.32M |
| July 29, 2026 | 111.39M |
| July 28, 2026 | 115.45M |
| July 27, 2026 | 116.81M |
| Date | Value |
|---|---|
| July 24, 2026 | 114.10M |
| July 23, 2026 | 117.26M |
| July 22, 2026 | 117.26M |
| July 21, 2026 | 114.10M |
| July 20, 2026 | 115.90M |
| July 17, 2026 | 113.20M |
| July 16, 2026 | 110.94M |
| July 15, 2026 | 115.00M |
| July 14, 2026 | 114.10M |
| July 13, 2026 | 117.26M |
| July 10, 2026 | 120.41M |
| July 09, 2026 | 118.16M |
| July 08, 2026 | 117.26M |
| July 07, 2026 | 117.71M |
| July 06, 2026 | 119.96M |
| July 02, 2026 | 118.61M |
| July 01, 2026 | 114.55M |
| June 30, 2026 | 119.51M |
| June 29, 2026 | 106.32M |
| June 26, 2026 | 104.98M |
| June 25, 2026 | 106.32M |
| June 24, 2026 | 104.08M |
| June 23, 2026 | 107.22M |
| June 22, 2026 | 107.22M |
| June 18, 2026 | 109.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arcutis Biotherapeutics, Inc. | 2.862B |
| ACADIA Pharmaceuticals, Inc. | 4.128B |
| Alnylam Pharmaceuticals, Inc. | 31.39B |
| Anika Therapeutics, Inc. | 269.22M |
| Savara, Inc. | 937.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.471M |
| Total Expenses (Quarterly) | 9.471M |
| EPS Diluted (Quarterly) | -0.2107 |
| Earnings Yield | -33.38% |
| Normalized Earnings Yield | -33.38 |